A Phase II Study of Pembrolizumab in EGFR Mutant, PD-L1+, Tyrosine Kinase Inhibitor (TKI) Naive Patients with Advanced NSCLC

被引：3
|
作者：
Lisberg, A. [1 ]
Hunt, J. [1 ]
Reese, N. [1 ]
Wang, T. [1 ]
Coluzzi, P. [1 ]
Spiegel, M. [1 ]
Bornazyan, K. [1 ]
Carroll, J. [1 ]
Madrigal, J. [1 ]
Ledezma, B. [1 ]
Mendenhall, M. [1 ]
Bui, J. [1 ]
Lu, H. [1 ]
Cummings, A. [1 ]
Noor, Z. [1 ]
Goldman, J. W. [1 ]
Garon, E. [1 ]
机构：
[1] Univ Calif Los Angeles, Los Angeles, CA USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
EGFR; NSCLC; anti-PD-1; therapy;
D O I：
10.1016/j.jtho.2017.09.456
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MA 02.07
引用
收藏
页码：S1805 / S1805
页数：1
相关论文
共 50 条
  • [31] Dynamics of Soluble PD-1 during Treatment with EGFR-TKI in Advanced NSCLC Patients
    Sorensen, Steffen F.
    Demuth, Christina
    Sorensen, Boe S.
    Meldgaard, Peter
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S602 - S602
  • [32] A phase I study of TQ-B2450, a PD-L1 mAb, plus anlotinib in EGFR plus advanced NSCLC patients failed to prior EGFR TKI therapies
    Feng, J.
    Shi, M.
    Wang, L.
    Yu, S.
    Yan, F.
    Peng, W.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S779 - S779
  • [33] EGFR MUTATION AND TYROSINE KINASE INHIBITOR (TKI) TREATMENT IN A DANISH (CAUCASIAN) POPULATION OF ADVANCED NSCLC PATIENTS AT ODENSE UNIVERSITY HOSPITAL 2010-11
    Kjeldsen, R.
    Hansen, K. H.
    Olsen, K. E.
    Hansen, N. G.
    Hansen, O.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (06) : S66 - S67
  • [34] A Multicenter, Randomized, Phase II Trial of EGFR TKI with Primary Tumor Resection for EGFR-Mutant Metastatic NSCLC Patients
    Chen, P. -H.
    Hsu, H. -H.
    Young, T. -H.
    Chen, J. -S.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S189 - S190
  • [35] Programmed death ligand-1 (PDL1) and CD3 co-expression in patients with advanced stage EGFR mutant NSCLC treated with EGFR tyrosine kinase inhibitors (TKI)
    Soo, R. A.
    Kim, H. R.
    Asuncion, B. R.
    Fazreen, Z.
    Omar, M. F. M.
    Herrera, M. C.
    Lim, J. S. Y.
    Sia, G.
    Soong, R.
    Cho, B. -C.
    ANNALS OF ONCOLOGY, 2015, 26 : 3 - 4
  • [36] Tepotinib with an EGFR-tyrosine kinase inhibitor in patients with EGFR-mutant MET-amplified NSCLC: A case series
    Lam, Wei-Sen
    Le, Xiuning
    Eisert, Anna
    Himpe, Ulrike
    De Bondt, Charlotte
    Mazieres, Julien
    Petrini, Iacopo
    Tho, Lye Mun
    Ahmad, Azura
    Chik, Yin Kwan Jeannie
    Lee, Wai Chung Kirsty
    Yang, Tsung-Ying
    Hsia, Te-Chun
    Joshi, Kirti
    Berghoff, Karin
    Vlassak, Soetkin
    Karachaliou, Niki
    Young, Louise
    van der Wekken, Anthonie
    RESPIROLOGY, 2023, 28 : 14 - 15
  • [37] A Phase 2 Study of TH-4000 in Patients with EGFR Mutant, T790M-Negative, Advanced NSCLC Progressing on an EGFR TKI
    Liu, Stephen V.
    Aggarawal, Charu
    Carter, Corey
    Gerber, David E.
    Gitlitz, Barbara J.
    Horn, Leora
    Solomon, Benjamin J.
    Stinchcombe, Thomas E.
    Villaruz, Liza
    West, Howard
    Kroll, Stew
    Pearce, Tillman
    Carnidge, Ross
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S429 - S430
  • [38] RAMOSE: An Open-Label Randomized Phase II Study of Osimertinib with or without Ramucirumab in TKI-Naive EGFR-Mutant Metastatic NSCLC
    Saltos, A.
    Baik, C.
    Sanborn, R. E.
    Shum, E.
    Kim, C.
    Hall, R.
    Fidler, M. J.
    Shu, C. A.
    Otterson, G.
    Patel, J.
    Wong, K.
    Hanna, N.
    Gray, J.
    Heymach, J.
    Le, X.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S614 - S614
  • [39] An Open-Label Randomized Phase II Study of Combining Osimertinib With and Without Ramucirumab in TKI-Naive EGFR-Mutant Metastatic NSCLC
    Le, X.
    Zhu, V.
    Saltos, A.
    Nikolinakos, P.
    Mileham, K.
    Velcheti, V.
    Husain, H.
    Nilsson, M.
    Tran, H.
    Roarty, E.
    Kim, E.
    Ou, S.
    Sanborn, R.
    Gray, J. E.
    Wong, K.
    Hanna, N.
    Papadimitrakopoulou, V.
    Heymach, J.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S838 - S838
  • [40] Phase II trial of XL184 (cabozantinib) plus erlotinib in patients (pts) with advanced EGFR-mutant non-small cell lung cancer (NSCLC) with progressive disease (PD) on epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy: A California Cancer Consortium phase II trial (NCI 9303)
    Reckamp, Karen L.
    Frankel, Paul Henry
    Mack, Philip C.
    Gittitz, Barbara Jennifer
    Ruel, Nora
    Lara, Primo
    Li, Tianhong
    Koczywas, Marianna
    Gadgeel, Shirish M.
    Cristea, Mihaela C.
    Belani, Chandra Prakash
    Newman, Edward M.
    Gandara, David R.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345